Trazodone controlled-release

Drug Profile

Trazodone controlled-release

Alternative Names: AF-1161; DDS-04A; Extended release trazodone - Labopharm; Oleptro; Trazodone Contramid OAD (TCOAD) - Labopharm; Trazodone HCl - Labopharm; Trazodone OAD; Triticum AC; Trittico

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Angelini Group; Labopharm
  • Developer Altus Formulation Inc; Angelini Group; Lees Pharmaceutical Holdings
  • Class Antidepressants; Erectile dysfunction therapies; Piperazines; Pyridones; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Diabetic neuropathies; Insomnia

Most Recent Events

  • 23 Feb 2017 Phase-II clinical trials in Diabetic neuropathies in Hungary (PO) (EudraCT2016-002772-27)
  • 27 May 2016 Lee's Pharmaceutical plans two phase I pharmacokinetics trials in Healthy volunteers in China (PO) (NCT02785614; NCT02785601)
  • 10 Sep 2015 Phase-II clinical trials in Insomnia in Italy (PO) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top